Here’s what you need to know.
1. The trial will be used to support a premarket approval application which will allow the GelrinC to be marketed in the U.S.
2. Focal defects of in the cartilage of the knee are caused by a result of trauma and can be painful to patients. They often require intervention.
The GelrinC is minimally invasive. It is administered as a liquid, and then is converted into a solid after being exposed to ultraviolet light. The implant degrades within six months to a year, and is replaced with functional and durable cartilage.
3. Rush University Medical Center’s Assistant Chairman and Professor in the department of Orthopedics Brian Cole, MD, said, “GelrinC is a potential game changer in the cartilage repair space, and can be an attractive and viable option for patients.”
More orthopedic device news:
6 key observations on robotic technology for spine surgery
Global spine surgical robots market to spike to $2.77B by 2022: 5 observations
AMA includes 1st endoscopic spine surgery code in 2017 codebook: 6 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
